Several assays exist to determine receptor status in ovarian cancers, like radio ligand binding assays, biochemical analysis, and even Northern blotting. However, patholo- gists generally prefer to judge the presence of biological markers in the context of tissue architecture, using immunohistochemistry (IHC). This allows for a better appreciation of exactly what in a tumor is positive for staining, and what is not.
